Know Cancer

or
forgot password


Phase 4
6 Months
21 Years
Not Enrolling
Both
Rhabdomyosarcoma

Thank you

Trial Information


Inclusion Criteria:



- child

- non metastatic rhabdomyosarcoma

- adequate heart, kidney, liver function

Exclusion Criteria:

- age over 21 years, under 6 months

- metastatic disease

- heart, kidney, liver disease

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label

Outcome Measure:

event free survival

Principal Investigator

Iris Kventsel, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Sheba Medical Center

Authority:

Israel: Israeli Health Ministry Pharmaceutical Administration

Study ID:

SHEBA-06-4013-IK-CTIL

NCT ID:

NCT00339118

Start Date:

Completion Date:

Related Keywords:

  • Rhabdomyosarcoma
  • Rhabdomyosarcoma
  • Sarcoma

Name

Location